Supernus Pharma (SUPN) Tops Q4 EPS by 5c, Revenues Miss; Offers FY21 Revenue Guidance Below Consensus

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.57, $0.05 better than the analyst estimate of $0.52. Revenue for the quarter came in at $143.56 million versus the consensus estimate of $146.19 million.

“We reported record revenues and operating earnings in 2020 based on the growth of Trokendi XR and Oxtellar XR and the addition of the CNS products acquired during the year,” said Jack Khattar, President and CEO of Supernus Pharmaceuticals. “Looking ahead, we are preparing for the expected launch of SPN-812 in the second quarter of 2021 and are excited to bring a novel non-stimulant treatment option to the millions of children and adolescents across the U.S. with ADHD.”

GUIDANCE:

Supernus Pharma sees FY2021 revenue of $550-580 million, versus the consensus of $581.47 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• People Inc. names new chief accounting officer as predecessor retires
• AXT appoints Tracy Liu to its board of directors